Shooting the Messenger to Treat Hypertriglyceridemia
Published April 7, 2024
DOI: 10.1056/NEJMe2402653
Abstract
This editorial describes the science behind an antisense drug targeting APOC3 mRNA to treat hypertriglyceridemia.
Continue reading this article
Select an option below:
Create your account to get 2 free subscriber-only articles each month.
Get Free Access Now Subscribe For Full AccessNotes
This editorial was published on April 7, 2024, and updated on April 11, 2024, at NEJM.org.
Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org.
Supplementary Material
Disclosure Forms (nejme2402653_disclosures.pdf)
- Download
- 167.03 KB
Information & Authors
Information
Published In
New England Journal of Medicine
Editor
Elizabeth G. Phimister, Ph.D., Editor
Copyright
Copyright © 2024 Massachusetts Medical Society. All rights reserved.
History
Published online: April 7, 2024
Topics
Authors
Affiliations
From the Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, and the Medical School of the University of Western Australia — both in Perth, Australia.
Metrics & Citations
Metrics
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.